Table 3.
ID | Description | p-value | p-adjusted value | # of hits |
---|---|---|---|---|
hsa03050 | Proteasome | 1.55E-11 | 4.78E-09 | 31 |
hsa04723 | Retrograde endocannabinoid signaling | 3.46E-10 | 4.78E-08 | 66 |
hsa05010 | Alzheimer's disease | 4.64E-10 | 4.78E-08 | 73 |
hsa00190 | Oxidative phosphorylation | 3.85E-09 | 2.98E-07 | 59 |
hsa05016 | Huntington's disease | 1.60E-08 | 9.90E-07 | 76 |
hsa04714 | Thermogenesis | 2.54E-08 | 1.31E-06 | 86 |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 2.98E-06 | 1.32E-04 | 57 |
hsa04721 | Synaptic vesicle cycle | 4.57E-06 | 1.77E-04 | 30 |
hsa05012 | Parkinson's disease | 1.51E-05 | 5.18E-04 | 53 |
hsa04728 | Dopaminergic synapse | 6.48E-05 | 0.002003299 | 48 |
hsa04724 | Glutamatergic synapse | 1.58E-04 | 0.004085366 | 42 |
hsa05169 | Epstein-Barr virus infection | 1.59E-04 | 0.004085366 | 66 |
hsa04720 | Long-term potentiation | 1.73E-04 | 0.004119762 | 28 |
hsa04727 | GABAergic synapse | 2.31E-04 | 0.00506623 | 34 |
hsa01200 | Carbon metabolism | 2.46E-04 | 0.00506623 | 42 |
hsa01521 | EGFR tyrosine kinase inhibitor resistance | 3.12E-04 | 0.006031187 | 31 |
hsa04725 | Cholinergic synapse | 4.73E-04 | 0.008596289 | 40 |
hsa00270 | Cysteine and methionine metabolism | 5.56E-04 | 0.009547497 | 20 |
hsa04911 | Insulin secretion | 5.99E-04 | 0.009738112 | 32 |
hsa04713 | Circadian entrainment | 6.78E-04 | 0.01048273 | 35 |
hsa05033 | Nicotine addiction | 8.70E-04 | 0.012730978 | 18 |
hsa00650 | Butanoate metabolism | 9.06E-04 | 0.012730978 | 14 |
hsa03010 | Ribosome | 0.0010736 | 0.014423588 | 50 |
hsa04510 | Focal adhesion | 0.001159439 | 0.014927779 | 62 |
hsa04390 | Hippo signaling pathway | 0.001260878 | 0.015584456 | 50 |